Telomerase and cancer

Human Molecular Genetics

Volumn 10, Issue 7, 2001, Pages 677-685

  Shay, Jerry W ^a   Zou, Ying ^a   Hiyama, Eiso ^b   Wright, Woodring E ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BINDING PROTEIN; DNA; DNA BINDING PROTEIN; HOLOENZYME; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; RIBONUCLEOPROTEIN; RNA BINDING PROTEIN; SMALL NUCLEOLAR RNA; TELOMERASE; TELOMERASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; CANCER; CANCER CELL; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER SCREENING; CELL DIVISION; CELL FUNCTION; CELL PROLIFERATION; CONTROLLED STUDY; DNA DAMAGE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVIEW; TELOMERE;

EUKARYOTA;

EID: 0035059660     PISSN: 09646906     EISSN: None     Source Type: Journal    
DOI: 10.1093/hmg/10.7.677     Document Type: Review

References (170)

1. The hallmarks of cancer
2. Defining the molecular mechanisms of human cell immortalization
3. Creation of human tumour cells with defined genetic elements
4. The multistep nature of cancer
5. Telomere dynamics in cancer progression and prevention: Fundamental differences in human and mouse telomere biology
6. The limited in vitro lifetime of human diploid cell strains
7. Haylick, his limit, and cellular aging
8. Telomeres and senescence: The history, the experiment, the future
9. Replicative senescence-an old lives tale
10. The two-stage mechanism controlling cellular senescence and immortalization
11. Telomere loss: Mitotic clock or genetic time bomb?
12. Telomeres shorten during aging
13. Telomere reduction in human colorectal carcinoma and with aging
14. Structure and variability of human chromosome ends
15. In vivo loss of telomeric repeats with age in humans
16. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity
17. Experimental elongation of telomeres in immortal human cells extends the lifespan of immortal x normal cell hybrids
18. Extension of life-span by introduction of telomerase into normal human cells
19. Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span
20. Telomerase activity is sufficient to allow transformed cells to escape from crisis
21. n, present at the telomeres of human chromosomes
22. The end of the (DNA) line
23. Telomere shortening is proportional to the size of the 3′ G-rich telomeric overhang
24. Origin of concatameric T4 DNA
25. A theory of marginotomy. The incomplete copying of template margin in enzymic synthesis of polynucleotides and biological significance of the phenomenon
26. Telomerases
27. The telomerase reverse transcriptase: Components and regulation
28. Telomerase and the maintenance of chromosome ends
29. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts
30. The human telomerase terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats
31. Reverse transcriptase motifs in the catalytic subunit of telomerase
32. Telomerase catalytic subunit homologs from fission yeast and humans
33. Reconstitution of human telomerase with the catalytic protein subunit hTRT
34. Telomerase activity in human germline and embryonic tissues and cells
35. Specific association of human telomerase activity with immortal cells and cancer
36. A survey of telomerase activity in human cancer
37. The RNA component of human telomerase
38. Telomerase activity in human cancer
39. The reactivation of telomerase activity in cancer progression
40. Role of telomerase in cellular proliferation and cancer
41. Cellular senescence as a tumor-protection mechanism: The essential role of counting
42. Aging and cancer: Are telomeres and telomerase the connection?
43. Telomere elongation in immortal human cells without detectable telomerase activity
44. Heterogeneity in telomere length of human chromosomes
45. Telomere length predicts replicative capacity of human fibroblasts
46. Telomerase expression in human somatic cells does not induce changes associated with a transformed phenotype
47. Absence of cancer-associated changes in human fibroblasts immortalized with telomerase
48. Dissociation among in vitro telomerase activity, telomerase maintenance, and cellular immortalization
49. The establishment of telomerase-immortalized cell lines representing human chromosome instability syndromes
50. Human endothelial cell life extension by telomerase expression
51. Formation of functional tissue from transplanted adrenocortical cells expressing telomerase reverse transcriptase
52. The use of telomerized cells for tissue engineering
53. Telomerase prevents the accelerated cell ageing of Werner syndrome fibroblasts
54. Telomerase extends the lifespan of virus-transformed human cells without net telomere lengthening
55. A human telomeric protein
56. Human telomeres contain two distinct Myb-related proteins, TRF1 and TRF2
57. TRF2 protects human telomeres from end-to-end fusions
58. Control of telomere length by the human telomeric protein TRF1
59. Control of human telomere length by TRF1 and TRF2
60. TRF1 binds a bipartite telomeric site with extreme spatial flexibility
61. At the end of the millennium a view of the end
62. Telomere length regulation
63. Tankyrase, a poly(ADP-ribose) polymerase at human telomeres
64. Tankyrase promotes telomere elongation in human cells
65. Telomeric localization of TRF2, a novel human telobox protein
66. Cell cycle dependent localization of the telomeric PARP, tankyrase, to nuclear pore complexes and centrosomes
67. TIN2, a new regulator of telomere length in human cells
68. Identification of human Rap 1: Implications for telomere evolution
69. Cell-cycle-regulated association of RAD50/MRE11/NBS1 with TRF2 and human telomeres
70. Ku binds telomeric DNA in vitro
71. Ku acts in a unique way at the mammalian telomere to prevent end joining
72. n
73. Telomere elongation by hnRNP A1 and a derivative that interacts with telomeric repeats and telomerase
74. In vitro properties of the conserved mammalian protein hnRNP D suggest a role in telomere maintenance
75. Heterogeneous nuclear ribonucleoprotein A1 and UP1 protect mammalian telomeric repeats and modulate telomere replication in vitro
76. Influence of ATM function on telomere metabolism
77. Altered telomere nuclear matrix interactions and nucleosomal periodicity in cells derived from individuals with ataxia telangiectasia before and after ionizing radiation treatment
78. Characterization of ataxia telangiectasia fibroblasts with extended life-span through telomerase expression
79. Functions of poly(ADP-ribose) polymerase in controlling telomere length and chromosomal stability
80. Mammalian telomeres end in a large duplex loop
81. A box H/ACA small nucleolar RNA-like domain at the human telomerase RNA 3′ end
82. Secondary structure of vertebrate telomerase RNA
83. Nucleolar localization signals of Box H/ACA small nucleolar RNAs
84. The telomere terminal transferase of Tetrahymena is a ribonucleoprotein enzyme with two kinds of primer specificity
85. The telomerase RNA pseudoknot is critical for the stable assembly of a catalytically active ribonucleoprotein
86. Heterogeneous nuclear ribonucleoproteins C1 and C2 associate with human telomerase
87. Telomerase RNA bound by protein motifs specific to telomerase reverse transcriptase
88. Human telomerase activation requires two independent interactions between telomerase RNA and telomerase reverse transcriptase
89. Two inactive fragments of the integral RNA cooperate to assemble active telomerase with the human protein catalytic subunit (hTERT) in vitro
90. Gbp 1p, a protein with RNA recognition motifs, binds single-stranded telomeric DNA and changes its binding specificity upon dimerization
91. Mutant dyskerin ends relationship with telomerase
92. A telomerase component is defective in the human disease dyskeratosis congenita
93. Identification of two RNA-binding proteins associated with human telomerase RNA
94. A mammalian telomerase-associated protein
95. Vaults and telomerase share a common subunit, TEP1
96. In vitro assembly of human H/ACA small nucleolar RNPs reveals unique features of U17 and telomerase RNAs
97. Functional requirement of p23 and Hsp90 in telomerase complexes
98. Heterogeneous nuclear ribonucleoprotein A1 and UP1 protect mammalian telomeric repeats and modulate telomere replication in vitro
99. n
100. The La antigen associates with the human telomerase ribonucleoprotein and influences telomere length in vivo
101. A role for the yeast La protein in U6 snRNP assembly: Evidence that the La protein is a molecular chaperone for RNA polymerase III transcripts
102. Precursors to the U3 small nucleolar RNA lack small nucleolar RNP proteins but are stabilized by La binding
103. The La protein in Schizosaccharomyces pombe: A conserved yet dispensable phosphoprotein that functions in tRNA maturation
104. Telomerase and early detection of cancer: A national cancer institute workshop
105. Telomerase in cancer: Diagnostic, prognostic and therapeutic implications
106. Methods for analysis of telomerase and telomeres
107. Detection of telomerase activity in human cells and tumors by a telomeric repeat amplification protocol (TRAP)
108. Comparison of the telomeric repeat amplification protocol (TRAP) to the new TRAP-eze telomerase detection kit
109. Modification of a telomeric repeat amplification protocol (TRAP) results in increased reliability, linearity and sensitivity
110. A non-radioactive fluorescence-based telomeric repeat amplification protocol to detect and quantitate telomerase activity
111. Cytological detection of telomerase activity using an in situ telomeric repeat amplification protocol assay
112. Enhanced detection of telomerase activity in tumor derived human cell lines
113. Telomerase activity in small-cell and non-small-cell lung cancers
114. Correlating telomerase activity levels with human neuroblastoma outcomes
115. Telomerase activity in human brain tumors
116. Telomerase activity: A prevalent marker of malignant human prostate tissue
117. Telomerase activity in human breast tumors
118. Human telomerase RNA levels in immortal cell lines and tumor tissues
119. Telomerase activity in malignant and nonmalignant skin conditions
120. Telomerase activity in human renal cell carcinoma
121. Telomeres and telomerase in human leukemias
122. Telomerase activity is detected in pancreatic cancer but not in benign pancreatic lesions
123. Expression of telomerase activity and in situ telomerase RNA expression in malignant and non-malignant lymph nodes
124. Clinical implications of telomerase activity levels in acute leukemia
125. Detection of human telomerase RNA (hTR) and telomerase activity in urine for diagnosis of bladder cancer
126. Telomerase expression during multistage pathogenesis of breast carcinoma
127. Expression of the RNA component of telomerase in Wilm's tumor and its precursor lesion recapitulates renal embryogenesis
128. Telomerase activity and expression of its RNA component in cervical lesions
129. In situ hybridization for the detection of telomerase RNA in the progression from Barrett's esophagus to esophageal adenocarcinoma
130. Progressive increase in telomerase activity from benign melanocytic conditions to malignant melanoma
131. High telomerase activity is an independent prognostic indicator of poor outcome in colorectal cancer
132. Telomerase activity as a marker of breast carcinoma in fine-needle aspirated samples
133. Immuno-histochemical detection of telomerase (hTERT) protein in human cancer tissues and a subset of cells in normal tissues
134. Telomerase in the early detection of cancer
135. Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death
136. Inhibition of the spontaneous immortalization of breast epithelial cells from individuals predisposed to breast cancer: Effects of chemopreventive and anti-telomerase agents
137. Inhibition of human telomerase activity by peptide nucleic acids
138. Telomerase inhibition by peptide nucleic acids reverses 'immortality' of transformed human cells
139. Decline in telomerase activity as a measure of tumor cell killing by antineoplastic agents in vitro
140. For better or worse? Telomerase inhibition and cancer
141. Applications of telomerase research in the fight against cancer
142. Telomerase inhibitors
143. Cellular delivery of peptide nucleic acids and inhibition of human telomerase
144. Telomerase: An unusual target for cytotoxic agents
145. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: Development of mean graph and COMPARE algorithm
146. FJ5002: A potent telomerase inhibitor identified by exploiting the disease-oriented screening program with COMPARE analysis
147. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes
148. Cytotoxic T cell immunity against telomerase reverse transcriptase in humans
149. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
150. Telomere shortening and apoptosis in telomerase-inhibited human tumor cells
151. Inhibition of telomerase limits the growth of human cancer cells
152. Toward identifying a cellular determinant of telomerase repression
153. Antisense oligonucleotides as therapeutic agents
154. Inhibitory effects of telomere-mimic phosphorotioate oligonucleotides on various human tumor cells in vitro
155. Inhibition of telomerase activity of melanoma cells in vitro by antisense oligonucleotide
156. A hexameric phosphorothioate oligonucleotide telomerase inhibitor arrests growth of Burkitt's lymphoma cells in vitro and in vivo
157. Targeted therapy of human malignant glioma in a mouse model by 2-5A antisense directed against telomerase RNA
158. 2-5A antisense directed against telomerase RNA produces apoptosis in ovarian cancer cells
159. Treatment of prostate cancer in vitro and in vivo with 2-5A-anti-telomerase RNA component
160. Attenuation of telomerase activity by a hammer-head ribozyme targeting the template region of telomerase RNA in endometrial carcinoma cells
161. Inhibition of telomerase activity by a hammerhead ribozyme targeting the RNA component of telomerase in human melanoma cells
162. Telomere shortening and apoptosis in telomerase-inhibited human tumor cells
163. Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortal human cell lines
164. Inhibition of cell growth and telomerase activity of breast cancer cells in vitro by 3′-azido-3′-deoxythymidine
165. Inhibition of telomerase activity and cell proliferation by a reverse transcriptase inhibitor in gynaecological cancer cell lines
166. Irreversible telomere shortening by 3′-azido-2′,3′-dideoxythymidine (AZT) treatment
167. Human telomerase inhibition by substituted acridine derivatives
168. Inhibition of human telomerase by a G-quadruplex-interactive compound
169. 2,7-disubstituted amido-fluorenone derivatives as inhibitors of human telomerase
170. Molecular modeling studies on G-quadruplex complexes of telomerase inhibitors: Structure-activity relationships